Department of Hepatobiliary Surgery, Zhuji City People's Hospital, Zhuji 311800, P.R.China.
Cell Mol Biol (Noisy-le-grand). 2020 Sep 30;66(6):135-141.
This study set out to observe the value of miR-885-5p in the prognosis evaluation of liver cancer patients after transcatheter arterial chemoembolization. Sixty liver cancer patients treated in Zhuji City People's Hospital between January 2019 and September 2019 were enrolled. The patients were categorized into survival (SG) and death groups (DG) according to prognosis. Sixty-five healthy individuals were included as a control. The expression of miR-885-5p and miR-21were measured by the qRT-PCR and predictive value of diagnostic efficiency was determined by the ROC curve. Multivariate Cox regression analysis was performed to explore independent risk factors. Results showed that levels of miR-885-5p in the serum of liver cancer patients were obviously lower than that of the control group; however, levels of miR-21 in the serum of liver cancer patients were higher than that of healthy individuals. Patients with miR-885-5p low expression and miR-21 high expression had poor differentiation, stages III+IV, and their incidence of lymphatic invasion and distal metastasis was higher (P<0.05). AUC values of miR-885-5p and miR-21 single diagnosis were both > 0.8. The relative level of miR-885-5p in the serum of the SG was dramatically higher than that of the DG, and its relative level of miR-21 in serum was significantly decreased compared with DG. ROC curves in diagnosing the prognosis of liver cancer patients were drawn, AUC values of serum miR-885-5p and miR-21 in diagnosing their prognosis were both > 0.8. Cox regression analysis was carried out on independent factors affecting their prognosis. The results revealed that the TNM stage, lymphatic invasion, distal metastasis and miR-885-5p were independent prognostic factors affecting their 5-year survival. It was concluded that miR-885-5p exhibited the potential to be a serum biomarker to evaluate the efficacy of advanced liver cancer.
本研究旨在观察 miR-885-5p 在肝癌患者经导管动脉化疗栓塞（TACE）治疗后预后评估中的价值。选取 2019 年 1 月至 2019 年 9 月诸暨市人民医院收治的 60 例肝癌患者，根据预后分为生存组（SG）和死亡组（DG）。另选取同期 65 例健康体检者作为对照组。采用 qRT-PCR 检测 miR-885-5p 和 miR-21 的表达，通过 ROC 曲线确定诊断效率的预测价值。采用多因素 Cox 回归分析探讨独立危险因素。结果显示，肝癌患者血清 miR-885-5p 水平明显低于对照组，而血清 miR-21 水平明显高于健康对照组。miR-885-5p 低表达和 miR-21 高表达患者分化差，分期为 III+IV 期，淋巴侵袭和远处转移发生率较高（P<0.05）。miR-885-5p 和 miR-21 单项诊断的 AUC 值均>0.8。SG 组血清 miR-885-5p 相对水平明显高于 DG 组，血清 miR-21 相对水平明显低于 DG 组。绘制诊断肝癌患者预后的 ROC 曲线，血清 miR-885-5p 和 miR-21 诊断其预后的 AUC 值均>0.8。对影响其预后的独立因素进行 Cox 回归分析，结果表明 TNM 分期、淋巴侵袭、远处转移和 miR-885-5p 是影响其 5 年生存率的独立预后因素。结论：miR-885-5p 有望成为评估晚期肝癌疗效的血清标志物。
